{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:45:51Z","timestamp":1772174751464,"version":"3.50.1"},"reference-count":28,"publisher":"Medknow","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["smedj"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.11622\/smedj.2019054","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T04:24:36Z","timestamp":1560486276000},"page":"474-478","source":"Crossref","is-referenced-by-count":12,"title":["Clinical spectrum, treatment and outcomes of uveal melanoma in a tertiary centre"],"prefix":"10.4103","volume":"60","author":[{"given":"W","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PS","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2581","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0161-6420(03)00077-0","article-title":"Survival rates with uveal melanoma in the United States: 1973-1997","volume":"110","author":"AD","year":"2003","unstructured":"1. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-5.","journal-title":"Ophthalmology"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.ophtha.2013.12.014","article-title":"A molecular revolution in uveal melanoma: implications for patient care and targeted therapy","volume":"121","author":"JW","year":"2014","unstructured":"2. Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology 2014; 121:1281-8.","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/08820538.2013.825290","article-title":"A review of advanced genetic testing for clinical prognostication in uveal melanoma","volume":"28","author":"Werdich","year":"2013","unstructured":"3. Werdich XQ, Jakobiec FA, Singh AD, Kim IK. A review of advanced genetic testing for clinical prognostication in uveal melanoma. Semin Ophthalmol 2013; 28:361-71.","journal-title":"Semin Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Diener-West M, Reynolds SM, Agugliaro DJ, et al; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123:1639-43.","DOI":"10.1001\/archopht.123.12.1639"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","unstructured":"5. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881-5.","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1167\/iovs.15-16532","article-title":"Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011)","volume":"56","author":"Park","year":"2015","unstructured":"6. Park SJ, Oh CM, Kim BW, et al. Nationwide incidence of ocular melanoma in South Korea by using the national cancer registry database (1999-2011). Invest Ophthalmol Vis Sci 2015; 56:4719-24.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ijc.20690","article-title":"International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification","volume":"114","author":"Stang","year":"2005","unstructured":"7. Stang A, Parkin DM, Ferlay J, J\u00f6ckel KH. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int J Cancer 2005; 114:114-23.","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/eye.2015.51","article-title":"Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture","volume":"29","author":"Shields","year":"2015","unstructured":"8. Shields CL, Kaliki S, Cohen MN, et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond) 2015; 29:1027-35.","journal-title":"Eye (Lond)"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol 1998; 125:767-78.","DOI":"10.1016\/S0002-9394(98)00038-5"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/sj.bjc.6602598","article-title":"Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS","volume":"92","author":"Zuidervaart","year":"2005","unstructured":"10. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005; 92:2032-8.","journal-title":"Br J Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","unstructured":"11. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-3.","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Gradle Lecture","volume":"124","author":"Shields","year":"2017","unstructured":"12. Shields CL, Say EAT, Hasanreisoglu M, et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: The 2017 Harry S. Gradle Lecture. Ophthalmology 2017; 124:1523-31.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Mortality in patients with small choroidal melanoma. COMS report no. 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997; 115:886-93.","DOI":"10.1001\/archopht.1997.01100160056009"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0161-6420(88)33086-1","article-title":"Enucleation versus plaque irradiation for choroidal melanoma","volume":"95","author":"Straatsma","year":"1988","unstructured":"14. Straatsma BR, Fine SL, Earle JD, et al. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology 1988; 95:1000-4.","journal-title":"Ophthalmology"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. Control Clin Trials 1993; 14:362-91.","DOI":"10.1016\/0197-2456(93)90052-F"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/bjo.86.3.333","article-title":"Mode of presentation and time to treatment of uveal melanoma in Finland","volume":"86","author":"Eskelin","year":"2002","unstructured":"16. Eskelin S, Kivel\u00e4 T. Mode of presentation and time to treatment of uveal melanoma in Finland. Br J Ophthalmol 2002; 86:333-8.","journal-title":"Br J Ophthalmol"},{"key":"ref16","unstructured":"17. Biswas J, Kabra S, Krishnakumar S, Shanmugam MP. Clinical and histopathological characteristics of uveal melanoma in Asian Indians. A study of 103 patients. Indian J Ophthalmol 2004; 52:41-4."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0974-620X.94766","article-title":"Clinicopathological correlation of choroidal melanoma in Indian population: a study of 113 cases","volume":"5","author":"Dhupper","year":"2012","unstructured":"18. Dhupper M, Biswas J, Gopal L, Kumar SK, Khetan V. Clinicopathological correlation of choroidal melanoma in Indian population: a study of 113 cases. Oman J Ophthalmol 2012; 5:42-5.","journal-title":"Oman J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Liu YM, Li Y, Wei WB, Xu X, Jonas JB. Clinical characteristics of 582 patients with uveal melanoma in China. PLoS One 2015; 10:e0144562.","DOI":"10.1371\/journal.pone.0144562"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/CMR.0000000000000375","article-title":"Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013","volume":"27","author":"Tomizuka","year":"2017","unstructured":"20. Tomizuka T, Namikawa K, Higashi T. Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013. Melanoma Res 2017; 27:492-7.","journal-title":"Melanoma Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","article-title":"Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients","volume":"119","author":"EM","year":"2012","unstructured":"21. Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology 2012; 119:1582-9.","journal-title":"Ophthalmology"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Ah-Fat FG, Damato BE. Delays in the diagnosis of uveal melanoma and effect on treatment. Eye (Lond) 1998; 12(Pt 5):781-2.","DOI":"10.1038\/eye.1998.202"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/bjc.2013.299","article-title":"Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11","volume":"109","author":"Koopmans","year":"2013","unstructured":"23. Koopmans AE, Vaarwater J, Paridaens D, et al. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer 2013; 109:493-6.","journal-title":"Br J Cancer"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","unstructured":"24. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191-9.","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Ominato J, Fukuchi T, Sato A, et al. The role of mutation rates of GNAQ or GNA11 in cases of uveal melanoma in Japan. Appl Immunohistochem Mol Morphol 2018; 26:658-63.","DOI":"10.1097\/PAI.0000000000000505"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Psinakis F, Katseli A, Koutsandrea C, et al. Uveal melanoma: GNAQ and GNA11 mutations in a Greek population. Anticancer Res 2017; 37:5719-26.","DOI":"10.21873\/anticanres.12010"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Xu X, Wei WB, Li B, et al. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese. PLoS One 2014; 9:e109699.","DOI":"10.1371\/journal.pone.0109699"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","article-title":"Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases","volume":"123","author":"Yavuzyigitoglu","year":"2016","unstructured":"28. Yavuzyigitoglu S, Koopmans AE, Verdijk RM, et al; Rotterdam Ocular Melanoma Study Group. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology 2016; 123:1118-28.","journal-title":"Ophthalmology"}],"container-title":["Singapore Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.smj.org.sg\/article\/clinical-spectrum-treatment-and-outcomes-uveal-melanoma-tertiary-centre","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:52:01Z","timestamp":1660042321000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.smj.org.sg\/article\/clinical-spectrum-treatment-and-outcomes-uveal-melanoma-tertiary-centre"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]},"published-print":{"date-parts":[[2019,9]]}},"URL":"https:\/\/doi.org\/10.11622\/smedj.2019054","relation":{},"ISSN":["0037-5675"],"issn-type":[{"value":"0037-5675","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}